Profiling of Secreted Immune Mediators in Neuroendocrine Tumors
Researcher: Matthew H. Kulke, MD Location: Dana-Farber Cancer Institute State: Massachusetts Year: 2016 Status: Active
Leave it blank
1. To characterize response to PD-1 inhibition in an established patient-derived ex-vivo tissue slice model of small intestine neuroendocrine tumors. We will identify differentially expressed genes and measure changes in soluble forms of immune checkpoint molecules and cytokines/chemokines in response to treatment.
2. To characterize secreted immune markers and cytokines in banked plasma of patients with advanced neuroendocrine tumors and to assess whether secretion patterns are associated with survival.
We propose to characterize the response of neuroendocrine tumors to PD-1 inhibition in an ex vivo tissue slice culture model. Using this model, we will assess changes in RNA expression and changes in secretion of key immune mediators in response to treatment. In parallel, we will characterize key secreted immune markers and cytokines in the plasma of patients with advanced neuroendocrine tumors, and assess whether secretion patterns are associated with overall survival. Our findings should provide preliminary evidence of whether immune checkpoint inhibition has a biologic effect on neuroendocrine tumors, and more broadly should provide insights as to the potential role of secreted immune mediators in regulating neuroendocrine tumor growth.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116